Acquisition Strengthens Aspire Pharma’s Strategic Portfolio
Petersfield, Hampshire, 17th October 2025 - Aspire Pharma Ltd, a rapidly growing UK-based specialty generics business, today announces the acquisition of Charlwood Pharma Ltd, a privately owned company specialising in the research & development of niche generic medicines.
The acquisition marks the culmination of a successful multi-year collaboration between the two organisations.
Charlwood brings to Aspire a robust pipeline of products spanning mental health, ear, nose and throat (ENT), cardiovascular and respiratory therapy areas - complementing Aspire’s existing portfolio and growth strategy.
Richard Condon, Aspire Pharma Chief Executive, said: “This acquisition not only strengthens our existing portfolio, but also stands as a testament to the value of long-term partnerships with Aspire, which deliver meaningful innovations that enhance patient care.
“Under the terms of this agreement, Aspire will assume full ownership of all intellectual property, which reinforces our ambitions for international expansion.
“This acquisition further demonstrates Aspire’s commitment to delivering quality, affordable medicines that support the highest levels of patient care, while offering true value to healthcare systems throughout the world.”
Editor Details
-
Company:
- Aspire Pharma
-
Name:
- karen tait
- Email:
-
Telephone:
- +447876886006
- Website:
